Sees FY25 gross margin mid 80%; non-GAAP operating expenses $380M-$400M; GAAP net income positive during 2H25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- FOLD Earnings this Week: How Will it Perform?
- Starbucks downgraded, Oracle initiated: Wall Street’s top analyst calls
- Amicus upgraded to Overweight from Equal Weight at Morgan Stanley
- Amicus Therapeutics Advances Pediatric Fabry Disease Study with Migalastat
- Amicus Therapeutics Advances Pompe Disease Research with New Observational Study